IRVINE, Calif., May 2, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its founder and Chief Executive Officer, Brian Meshkin, will speak at the 5th annual 10x Medical Device Conference which takes place in San Diego from May 1-3, 2017. This event is the annual in-person reunion for the Medical Devices Group. With more than 345,000 members, it is the world's largest medical device community.
On Wednesday morning, Brian Meshkin will speak about "Realizing Precision Medicine – Especially as it Relates to Pain Management." Having founded Proove over 7 years ago, Meshkin brings a unique perspective. While overcoming many challenges due to funding and growth, Meshkin has led Proove to become one of the fastest growing and successful technology companies in North America.
"It's an honor to be invited and to participate in this event which brings together so many leaders in the field of medical devices," explains Proove CEO Brian Meshkin.
Joe Hage, the leader of the Medical Devices Group, states, "The Medical Devices Group is the world's largest medical device community and the industry's only spam-free, curated forum for intelligent conversations with medical device thought leaders. I heard Brian speak at another event and was particularly impressed with his understanding of precision medicine, vision for the future, and ability to engage the audience. Precision medicine is an important trend impacting medical devices and there will be many entrepreneurs attending who can learn from the experiences faced by Brian and Proove. I was excited when Brian accepted our invitation."
About Proove Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
SOURCE Proove Biosciences, Inc.